** Exact Sciences EXAS.O falls 10% to $42.20 after blood colorectal cancer $(CRC)$ test did not meet expectations in trial
** Brokerage BTIG calls it a "worst case scenario"
** This also overshadowed a strong beat and raise Q2
** EXAS on Weds inked deal for exclusive rights to Freenome's blood-based screening CRC test, but analysts noted this excluded multi-cancer tests, which disappointed investors
** At least six brokerages cut price targets
** Shares of rival Guardant Health GH.O gain nearly 17%
** Canaccord Genuity says GH's Shield test performance is a touch better than Freenome's test
** EXAS stock down 27% YTD while GH has surged nearly 70%
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.